Sotalol: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
No edit summary
Line 1: Line 1:
{{Sotalol}}
{{DrugProjectFormSinglePage
{{drugbox |
|genericName=generic name
| IUPAC_name = ''N''-[4-(1-hydroxy-2-isopropylamino-<br>ethyl)-phenyl]-methanesulfonamide
|aOrAn=a
| image = Sotalol.png
|drugClass=Adrenergic receptor agonist
| CAS_number = 3930-20-9
|indication=a list of indications, separated by commas.
| ATC_prefix=C07
|hasBlackBoxWarning=Yes
| ATC_suffix=AA07
|adverseReactions=a list of adverse reactions, separated by commas.
| PubChem=5253
|blackBoxWarningTitle=Warning Title
| DrugBank=
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| C=12 | H=20 | N=2 | O=3 | S=1
|fdaLIADAdult======Condition 1=====
| molecular_weight = 272.3624 g/mol
 
| bioavailability = >95%
* Dosing Information
| metabolism = Not metabolised
 
| elimination_half-life = 12 hours
:* (Dosage)
| excretion = [[Kidney|Renal]] <br> [[Mammary gland|Lactic]] (In lactating females)
 
| pregnancy_AU =
=====Condition 2=====
| pregnancy_US = B
 
| pregnancy_category =
* Dosing Information
| legal_status = Rx-only
 
| routes_of_administration = oral
:* (Dosage)
}}
|offLabelAdultGuideSupport======Condition 1=====
__NOTOC__
 
{{CMG}}
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
|offLabelAdultNoGuideSupport======Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:* (Dosage)
|fdaLIADPed======Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
|offLabelPedGuideSupport======Condition 1=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
|offLabelPedNoGuideSupport======Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:* (Dosage)
|contraindications=* Condition 1
* Condition 2
* Condition 3
* Condition 4
* Condition 5
|warnings======Conidition 1=====
 
(Description)
 
|clinicalTrials=======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
 
=====Condition 2=====
 
======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
|postmarketing=(Description)
|drugInteractions=* Drug 1
* Drug 2
* Drug 3
* Drug 4
* Drug 5
 
=====Drug 1=====
 
(Description)
 
=====Drug 2=====
 
(Description)
 
=====Drug 3=====
 
(Description)
 
=====Drug 4=====
 
(Description)
 
=====Drug 5=====
 
(Description)
|useInPregnancyFDA=(Description)
|useInPregnancyAUS=(Description)
|useInLaborDelivery=(Description)
|useInNursing=(Description)
|useInPed=(Description)
|useInGeri=(Description)
|useInGender=(Description)
|useInRace=(Description)
|useInRenalImpair=(Description)
|useInHepaticImpair=(Description)
|useInReproPotential=(Description)
|useInImmunocomp=(Description)
|othersTitle=Others
|useInOthers=(Description)
 
|administration=(Oral/Intravenous/etc)
|monitoring======Condition 1=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 2=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 3=====
 
(Description regarding monitoring, from ''Warnings'' section)
|IVCompat====Solution===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Y-Site===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Admixture===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Syringe===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====


'''''For patient information about Sotalol, click [[Sotalol (patient information)|here]].'''''
* Solution 1
* Solution 2
* Solution 3


{{SB}} BETAPACE, SOTALOL HYDROCHLORIDE
===TPN/TNA===


==Overview==
====Compatible====


'''Sotalol''' (trade names '''Betapace''' and '''Betapace AF''', [[Berlex Laboratories]]) is a [[medication|drug]] used in individuals with rhythm disturbances ([[cardiac arrhythmia]]s) of the [[heart]], and to treat [[hypertension]] in some individuals.
* Solution 1
* Solution 2
* Solution 3


==Category==
====Not Tested====


Beta Blockers
* Solution 1
* Solution 2
* Solution 3


==FDA Package Insert==
====Variable====


====BETAPACE (sotalol hydrochloride) tablet====
* Solution 1
* Solution 2
* Solution 3


'''  [[Sotalol tablet indications and usage|Indications and Usage]]'''
====Incompatible====
'''| [[Sotalol tablet dosage and administration|Dosage and Administration]]'''
'''| [[Sotalol tablet contraindications|Contraindications]]'''
'''| [[Sotalol tablet warnings and precautions|Warnings and Precautions]]'''
'''| [[Sotalol tablet adverse reactions|Adverse Reactions]]'''
'''| [[Sotalol tablet drug interactions|Drug Interactions]]'''
'''| [[Sotalol tablet use in specific populations|Use in Specific Populations]]'''
'''| [[Sotalol tablet overdosage|Overdosage]]'''
'''| [[Sotalol tablet description|Description]]'''
'''| [[Sotalol tablet clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Sotalol tablet clinical studies|Clinical Studies]]'''
'''| [[Sotalol tablet how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Sotalol tablet labels and packages|Labels and Packages]]'''


{|
* Solution 1
| [[File:Sotabb1.png|thumb|800px]]
* Solution 2
|}
* Solution 3
|overdose====Acute Overdose===


====SOTALOL HYDROCHLORIDE injection====
====Signs and Symptoms====


'''  [[Sotalol injection indications and usage|Indications and Usage]]'''
(Description)
'''| [[Sotalol injection dosage and administration|Dosage and Administration]]'''
'''| [[Sotalol injection dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Sotalol injection contraindications|Contraindications]]'''
'''| [[Sotalol injection warnings and precautions|Warnings and Precautions]]'''
'''| [[Sotalol injection adverse reactions|Adverse Reactions]]'''
'''| [[Sotalol injection drug interactions|Drug Interactions]]'''
'''| [[Sotalol injection use in specific populations|Use in Specific Populations]]'''
'''| [[Sotalol injection overdosage|Overdosage]]'''
'''| [[Sotalol injection description|Description]]'''
'''| [[Sotalol injection clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Sotalol injection nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Sotalol injection clinical studies|Clinical Studies]]'''
'''| [[Sotalol injection how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Sotalol injection patient counseling information|Patient Counseling Information]]'''
'''| [[Sotalol injection labels and packages|Labels and Packages]]'''


{|
====Management====
| [[File:Sotabb2.png|thumb|800px]]
|}


==Pharmacology==
(Description)


It falls into the class III [[antiarrhythmic agents]] because it inhibits the inward [[potassium]] [[ion channel]]s in the heart.  It is also a [[beta blocker]] because of its primary action on the &beta;-[[adrenergic receptor]]s in the heart.
===Chronic Overdose===


By blocking the [[potassium channel]]s, sotalol prolongs [[repolarization]], therefore lengthening the [[QT interval]] and decreasing [[automaticity]].
====Signs and Symptoms====


It also slows [[AV node|atrioventricular (AV) nodal]] conduction (beta-blocking effect).
(Description)


Sotalol is a [[racemic]] mix of D and L [[enantiomers]].  The ''L''-isomer is a [[beta blocker]].
====Management====


Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.
(Description)
|drugBox={{Drugbox2
| verifiedrevid =
| IUPAC_name =
| image =
| drug_name =


==Indications==
<!--Clinical data-->
| tradename =  
| MedlinePlus =  
| licence_US =  
| pregnancy_AU =
| pregnancy_US =
| legal_status =
| routes_of_administration =


Sotalol is used to treat [[ventricular tachycardia]]s as well as [[atrial fibrillation]]. Betapace AF is specifically labeled for [[atrial fibrillation]].
<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =


Some evidence suggests that sotalol should be avoided in the setting of decreased [[ejection fraction]] due to [[myocardial infarction|heart attack]].
<!--Identifiers-->
| CAS_number_Ref =
| CAS_number =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID =
| UNII_Ref =
| UNII =
| KEGG_Ref =
| KEGG =
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =


==References==
<!--Chemical data-->
| C= | H= | N= | O=
| molecular_weight =
| smiles =
| InChI =
| InChIKey =
| StdInChI_Ref =
| StdInChI =
| StdInChIKey_Ref =
| StdInChIKey =
| melting_point =
}}
|mechAction=(Description)
|structure=(Description with picture)
|PD=(Description)
|PK=(Description)
|nonClinToxic=(Description)
|clinicalStudies======Condition 1=====


{{Reflist|2}}
(Description)


==See Also==
=====Condition 2=====


*[[Antiarrhythmic agents]]
(Description)
*[[Beta blocker]]


{{beta blockers}}
=====Condition 3=====


[[Category:Antiarrhythmic agents]]
(Description)
[[Category:Beta blockers]]
|howSupplied=(Description)
[[Category:Cardiovascular Drugs]]
|fdaPatientInfo=(Patient Counseling Information)
[[Category:Drugs]]
|nlmPatientInfo=(Link to patient information page)
|lookAlike=* (Paired Confused Name 1a) — (Paired Confused Name 1b)
* (Paired Confused Name 2a) — (Paired Confused Name 2b)
* (Paired Confused Name 3a) — (Paired Confused Name 3b)
|drugShortage=Drug Shortage
}}

Revision as of 19:46, 8 July 2014

Sotalol
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

Overview

Sotalol is a Adrenergic receptor agonist that is FDA approved for the {{{indicationType}}} of a list of indications, separated by commas.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include a list of adverse reactions, separated by commas..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Contraindications

  • Condition 1
  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

Warnings

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
Conidition 1

(Description)

Adverse Reactions

Clinical Trials Experience

Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)
Condition 2
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)

Postmarketing Experience

(Description)

Drug Interactions

  • Drug 1
  • Drug 2
  • Drug 3
  • Drug 4
  • Drug 5
Drug 1

(Description)

Drug 2

(Description)

Drug 3

(Description)

Drug 4

(Description)

Drug 5

(Description)

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): (Description)
Pregnancy Category (AUS): (Description)

Labor and Delivery

(Description)

Nursing Mothers

(Description)

Pediatric Use

(Description)

Geriatic Use

(Description)

Gender

(Description)

Race

(Description)

Renal Impairment

(Description)

Hepatic Impairment

(Description)

Females of Reproductive Potential and Males

(Description)

Immunocompromised Patients

(Description)

Others

(Description)

Administration and Monitoring

Administration

(Oral/Intravenous/etc)

Monitoring

Condition 1

(Description regarding monitoring, from Warnings section)

Condition 2

(Description regarding monitoring, from Warnings section)

Condition 3

(Description regarding monitoring, from Warnings section)

IV Compatibility

Solution

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Y-Site

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Admixture

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Syringe

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

TPN/TNA

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Overdosage

Acute Overdose

Signs and Symptoms

(Description)

Management

(Description)

Chronic Overdose

Signs and Symptoms

(Description)

Management

(Description)

Pharmacology

Chemical structure of Sotalol
Sotalol
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem ?
Chemical data
Formula ?
Mol. mass ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

Mechanism of Action

(Description)

Structure

(Description with picture)

Pharmacodynamics

(Description)

Pharmacokinetics

(Description)

Nonclinical Toxicology

(Description)

Clinical Studies

Condition 1

(Description)

Condition 2

(Description)

Condition 3

(Description)

How Supplied

(Description)

Storage

There is limited information regarding Sotalol Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Sotalol |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Sotalol |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

(Patient Counseling Information)

Precautions with Alcohol

Alcohol-Sotalol interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Sotalol Brand Names in the drug label.

Look-Alike Drug Names

  • (Paired Confused Name 1a) — (Paired Confused Name 1b)
  • (Paired Confused Name 2a) — (Paired Confused Name 2b)
  • (Paired Confused Name 3a) — (Paired Confused Name 3b)

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Sotalol&oldid=990518"